title: The incidence of thrombovenous and thromboembolic complications in kidney transplant patients with recurrent glomerulonephritis is dependent on the occurrence of severe proteinuria.
abstract: BACKGROUND
  Patients with recurrent glomerulonephritis (RG) after kidney transplantation are at high risk for thromboembolic events but it is unclear when the risk begins to increase.
  
  
  METHODS
  We evaluated the risk for thrombovenous and thromboembolic complications in relation to the occurrence of severe proteinuria (> or = 2 g protein in 24-hour urine) in 15 renal allograft recipients with biopsy-proven RG, who had received 20 allografts RG. The total period of observation was 53 (10-91) months. The post-transplant period before the occurrence of severe proteinuria lasted 18 (1-34) months and the subsequent proteinuric period until the end of the study, 35 (9-85) months.
  
  
  RESULTS
  The monthly incidence of thrombovenous and thromboembolic complications was only 1/18 in the first period before and in contrast, 11/35 in the subsequent period after the occurrence of severe proteinuria. The mean urinary protein excretion increased from 0.4 +/- 0.1 g/day immediately after transplantation to 6.1 +/- 4.8 g/day at the end of the study (p < 0.001). During the same period there was a 1.2-fold increase of fibrinogen (from 366 +/- 88 to 442 +/- 120 mg/dl, p < 0.025) and a 1.2-fold decrease of antithrombin III (from 110 +/- 12 to 92 +/- 12%, p < 0.001). All thrombotic complications occurred in 6 patients with 9 grafts; at the end of the study this group showed higher fibrinogen concentrations (454 +/- 155 versus 433 +/- 89 mg/dl, NS) m and lower antithrombin III levels (88 +/- 11 versus 97 +/- 11%, p < 0.05) than the group without thrombotic complications.
  
  
  CONCLUSIONS
  In kidney transplant patients with RG a high risk for thrombovenous and thromboembolic complications can be obs- served after the occurrence of severe proteinuria; this can mainly be explained by high fibrinogen and low antithrombin III levels. Anticoagulation therapy should be started in patients with RG immediately after the occurrence of severe proteinuria.
authors: Second Department of Medicine, General Hospital Linz, Austria.
authors: G
authors: G
authors: Biesenbach
authors: O
authors: O
authors: Janko
authors: R
authors: R
authors: Hubmann
authors: C
authors: C
authors: Gross
authors: P
authors: P
authors: Brücke
mesh_terms: D000328:Adult; D000991:Antithrombins / Q000032:analysis; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005921:Glomerulonephritis / Q000209:etiology*; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011507:Proteinuria / Q000150:complications*; D012008:Recurrence; D013923:Thromboembolism / Q000209:etiology*; D013927:Thrombosis / Q000209:etiology*; D014184:Transplantation, Homologous
chemical_list: D000991:Antithrombins; D005340:Fibrinogen